Frontline Pembrolizumab Plus Lenvatinib Has Antitumor Activity in Non–clear Cell RCC

The first-line combination of lenvatinib and pembrolizumab elicited durable responses with a manageable safety profile in patients with non–clear cell renal cell carcinoma, according to findings from the phase 2 KEYNOTE-B61 trial.

Related Keywords

Vienna ,Wien ,Austria ,Memorial Sloan Kettering Cancer Center ,New York ,United States ,Manuela Schmidinger ,Chan Lee ,Database Consortium ,University Of Vienna ,International Metastatic ,Chung Han Lee ,Karnofsky Performance Status ,Medical University ,Pembrolizumab ,Lenvatinib ,Phase 2 Keynote B61 Trial Nct04704219 ,Asco 2023 ,